Table 1.
Variable | Derivation Cohort, n = 2631 | Validation Cohort, n = 963 | P Value |
---|---|---|---|
Demographics | |||
Age, yrs | 61.8 ± 11.6 | 61.3 ± 11.3 | 0.221 |
Female | 825 (31.4) | 278 (28.9) | 0.152 |
Medical history | |||
History of Diabetes Mellitus | 955 (36.3) | 296 (30.7) | 0.002 |
History of Hypertension | 1488 (56.6) | 550 (57.1) | 0.765 |
History of Dyslipidemia | 1734 (65.9) | 680 (70.6) | 0.008 |
Current/recent smoker | 1360 (51.7) | 499 (51.8) | 0.947 |
History of renal dysfunction | 212 (8.1) | 78 (8.1) | 0.967 |
History of MI | 186 (7.1) | 91 (9.4) | 0.018 |
Prior PCI | 205 (7.8) | 100 (10.4) | 0.014 |
Prior peripheral arterial disease | 26 (1.0) | 15 (1.6) | 0.155 |
Presentation | |||
SBP on admission, mm Hg | 134.4 ± 22.7 | 135.7 ± 22.6 | 0.136 |
Heart rate on admission, beats/min | 75.2 ± 14.2 | 75.3 ± 14.0 | 0.221 |
LVEF, % | 57.0 ± 9.6 | 58.6 ± 8.5 | <0.001 |
SI | 0.58 ± 0.15 | 0.57 ± 0.14 | 0.298 |
GRACE | 130.9 ± 35.3 | 119.3 ± 34.5 | <0.001 |
Diagnosis on admission | 0.028 | ||
Unstable Angia | 776 (29.5) | 302 (31.4) | |
NSTEMI | 869 (33.0) | 273 (28.3) | |
STEMI | 986 (37.5) | 388 (40.3) | |
Troponin-I on admission, ng/mL | 0.71 (0.01, 17.67) | 0.67 (0.01, 21.00) | 0.900 |
PCI details | |||
Left main disease | 249 (9.5) | 84 (8.7) | 0.497 |
Three-vessel disease | 806 (30.6) | 247 (25.6) | 0.004 |
Intra-aortic Balloon Pump | 135 (5.1) | 25 (2.6) | 0.001 |
TIMI flow grade 3 post PCI | 2622 (99.7) | 958 (99.5) | 0.450 |
Use of glycoprotein IIb/IIIa inhibitor | 827 (31.4) | 376 (39.0) | <0.001 |
Medical treatment at discharge | |||
Aspirin | 2532 (96.2) | 955 (99.2) | <0.001 |
Clopidogrel | 2511 (95.4) | 938 (97.4) | 0.008 |
Ticagrelor | 32 (1.2) | 12 (1.2) | 0.943 |
Statin | 2491 (94.7) | 947 (98.3) | <0.001 |
ACEI / ARBs | 1509 (57.4) | 401 (41.6) | <0.001 |
Beta-blockers | 1414 (53.7) | 386 (40.1) | <0.001 |
MI, myocardial infarction; bpm, beats per minute; LVEF, left ventricular ejection fraction; h, hour; PCI, percutaneous coronary intervention; ACEI / ARBs, Angiotensin-converting enzyme inhibitors / Angiotensin receptor blockers.